Results 101 to 110 of about 18,181 (226)

Automated Multienzyme Digestion Workflows for Confident Characterization of Challenging Posttranslational Modifications in Therapeutic Antibodies by LC–MS/MS

open access: yesRapid Communications in Mass Spectrometry, Volume 40, Issue 21, 15 November 2026.
ABSTRACT Rationale Non‐reduced trypsin digestion of therapeutic antibodies can generate large disulfide‐linked peptide complexes that exhibit poor chromatographic and mass spectrometric performance. This limits the confident characterization of posttranslational modifications (PTMs) in specific antibody regions, such as the heavy‐chain constant region ...
Nanna Sofie Eskesen   +10 more
wiley   +1 more source

The impact of financial incentives promoting biosimilar products in oncology: A quasi-experimental study using administrative data.

open access: yesPLoS ONE
BackgroundBiosimilars have the potential to save a significant amount of money in cancer treatment costs. However, barriers exist in the adoption of biosimilar products.
Hisashi Itoshima   +5 more
doaj   +1 more source

Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study

open access: yesBMC Ophthalmology
Purpose To compare the anatomical and visual outcomes in eyes with submacular hemorrhage (SMH) treated with a combination of ranibizumab (RBZ) either innovator or biosimilar (Razumab) and intravitreal perfluoropropane gas (C3F8).
Debdulal Chakraborty   +8 more
doaj   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

open access: yesAnnals of Clinical and Translational Neurology, Volume 13, Issue 11, Page 2336-2346, November 2026.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin   +11 more
wiley   +1 more source

Clinical considerations for biosimilar antibodies

open access: yes, 2013
Biosimilar agents are approximate copies of branded biologic therapies. Since the first biosimilar was authorized in the European Union in 2006, fifteen additional agents have been approved by the European Medicines Agency, including two biosimilar ...
Mellstedt, H
core   +1 more source

Biosimilars in practice: Discriminant factors influencing prescription decisions among physicians in Thailand.

open access: yesPLoS ONE
This study aimed to assess the discriminant factors and determine the cutoff value which can predict or classify the group of prescribed and non-prescribed biosimilar among Thai physicians.
Chaoncin Sooksriwong   +5 more
doaj   +1 more source

Beyond Drugs or Surgery: Precision and Equity in Obesity Care

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Ron T. Varghese   +4 more
wiley   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

open access: yesArthritis &Rheumatology, Volume 78, Issue 11, Page 2261-2273, November 2026.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher   +12 more
wiley   +1 more source

Clinical efficacy in trials comparing biosimilar and reference insulins.

open access: yes, 2018
Clinical efficacy in trials comparing biosimilar and reference insulins.
Carolyn Tieu (5117252)   +4 more
core   +1 more source

Capacity building in medicines development and regulation in Africa—Overview on recent progress

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3759-3769, November 2026.
Aims Despite advances in health research and digital innovation, many African countries continue to face substantial resource constraints, fragmented capacity‐building efforts and a shortage of skilled professionals in medicines development and regulatory science.
Tirhani Maluleke   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy